Unknown

Dataset Information

0

Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.


ABSTRACT: The role of inflammation in obesity-related pathologies is well established. We investigated the therapeutic potential of LipoxinA4 (LXA4:5(S),6(R),15(S)-trihydroxy-7E,9E,11Z,13E,-eicosatetraenoic acid) and a synthetic 15(R)-Benzo-LXA4-analog as interventions in a 3-month high-fat diet (HFD; 60% fat)-induced obesity model. Obesity caused distinct pathologies, including impaired glucose tolerance, adipose inflammation, fatty liver, and chronic kidney disease (CKD). Lipoxins (LXs) attenuated obesity-induced CKD, reducing glomerular expansion, mesangial matrix, and urinary H2O2. Furthermore, LXA4 reduced liver weight, serum alanine-aminotransferase, and hepatic triglycerides. LXA4 decreased obesity-induced adipose inflammation, attenuating TNF-? and CD11c(+) M1-macrophages (M?s), while restoring CD206(+) M2-M?s and increasing Annexin-A1. LXs did not affect renal or hepatic M?s, suggesting protection occurred via attenuation of adipose inflammation. LXs restored adipose expression of autophagy markers LC3-II and p62. LX-mediated protection was demonstrable in adiponectin(-/-) mice, suggesting that the mechanism was adiponectin independent. In conclusion, LXs protect against obesity-induced systemic disease, and these data support a novel therapeutic paradigm for treating obesity and associated pathologies.

SUBMITTER: Borgeson E 

PROVIDER: S-EPMC4584026 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


The role of inflammation in obesity-related pathologies is well established. We investigated the therapeutic potential of LipoxinA4 (LXA4:5(S),6(R),15(S)-trihydroxy-7E,9E,11Z,13E,-eicosatetraenoic acid) and a synthetic 15(R)-Benzo-LXA4-analog as interventions in a 3-month high-fat diet (HFD; 60% fat)-induced obesity model. Obesity caused distinct pathologies, including impaired glucose tolerance, adipose inflammation, fatty liver, and chronic kidney disease (CKD). Lipoxins (LXs) attenuated obesi  ...[more]

Similar Datasets

| S-EPMC9772058 | biostudies-literature
| S-EPMC3260795 | biostudies-literature
| S-EPMC2542432 | biostudies-literature
| S-EPMC524215 | biostudies-literature
| S-EPMC4560490 | biostudies-literature
| S-EPMC4663743 | biostudies-literature
| S-EPMC4889496 | biostudies-literature
| S-EPMC6366870 | biostudies-literature
| S-EPMC8401900 | biostudies-literature
| S-EPMC6699576 | biostudies-literature